Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
Novel chinone-, hydrochinone-, and naphthochinone-analogues target mitochondrial dysfunction and oxidative stress in Friedreich's ataxia, providing a potential cure beyond symptom management.
Patent Information
- Application Number
- AU2026203365
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2026-05-02
- Publication Date
- 2026-07-23
AI Technical Summary
There is a need for better drug candidates to address the symptoms and underlying mitochondrial dysfunction in Friedreich's ataxia, a fatal, monogenic, autosomal recessive disease caused by frataxin deficiency, which leads to mitochondrial iron overload, oxidative stress, and impaired respiratory chain function, with current treatments only managing symptoms and no cure available.
Development of novel therapeutic compounds, such as chinone-, hydrochinone-, and naphthochinone-analogues, which target mitochondrial function and oxidative stress, potentially addressing the root causes of Friedreich's ataxia by modulating iron homeostasis and reducing ferroptosis.
These compounds show promise in ameliorating mitochondrial dysfunction and reducing oxidative stress, offering a potential therapeutic approach beyond symptom management, although clinical trials are ongoing.